AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33188423 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined rice bran, flaxseed, and sesame seed oils (30 g per day for 8 weeks)
Number of subjects: 143
Study 33188423 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (control)
Number of subjects: 143
Study 33963734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) and amoxicillin along with standard nutrition counseling for 2-12 weeks
Number of subjects: 573
Study 33963734 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling alone for 6 weeks
Number of subjects: 573
Study 35188267 — intervention group
Group type: EXPERIMENTAL
Intervention: Raspberry leaf tea (RLT)
Number of subjects: 121
Study 34506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery without a short text reminder
Number of subjects: 375
Study 34506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery with a short message reminder (SMS)
Number of subjects: 375
Study 34506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery without SMS
Number of subjects: 375
Study 34506503 — intervention group
Group type: COMPARATOR
Intervention: Facility-based delivery without a short text reminder (Control)
Number of subjects: 375
Study 34506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based delivery with a short message reminder
Number of subjects: 375
Study 34506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery utilizing Community Health Workers (CHWs)
Number of subjects: 375
Study 36241705 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN
Number of subjects: 80
Study 36241705 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study 32870416 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention (PLF) for 10 weeks
Number of subjects: 68
Study 32870416 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 68
Study 33361021 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO‐B inhibitor (Selegiline 5 mg)
Number of subjects: 120
Study 33361021 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (DNP 10 mg daily)
Number of subjects: 120
Study 36435988 — intervention group
Group type: EXPERIMENTAL
Intervention: CII elastics (100-150 g/side), full time
Number of subjects: 43
Study 36435988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CII elastics)
Number of subjects: 43
Study 33177131 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep electroacupuncture with strong deqi
Number of subjects: 44
Study 33177131 — intervention group
Group type: COMPARATOR
Intervention: Shallow electroacupuncture with no deqi
Number of subjects: 44
Study 33611331 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-massage (10 minutes)
Number of subjects: 73
Study 33611331 — intervention group
Group type: COMPARATOR
Intervention: Control group (fabric ring massage)
Number of subjects: 73
Study 32795086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 32795086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study 35805761 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-generated summary text about HPV (n = 193)
Number of subjects: 386
Study 35805761 — intervention group
Group type: COMPARATOR
Intervention: Original text about HPV (n = 193)
Number of subjects: 386
Study 34551936 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 0
Study 34551936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33556410 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + saffron supplement (150 mg after each session)
Number of subjects: 28
Study 33556410 — intervention group
Group type: COMPARATOR
Intervention: RT + placebo (dextrose pill)
Number of subjects: 28
Study 33556410 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + saffron supplement
Number of subjects: 28
Study 33556410 — intervention group
Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 28
Study 33176899 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108
Study 33176899 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-OH-risperidone
Number of subjects: 108
Study 33176899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active moiety (combined concentrations)
Number of subjects: 108
Study 33176899 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based predictions
Number of subjects: 108
Study 32696559 — intervention group
Group type: EXPERIMENTAL
Intervention: risk-guided nurse intervention (DMP-Plus group)
Number of subjects: 404
Study 32696559 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 404
Study 36286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic treatment (Zacofalk) in subgroup Ia (n=58)
Number of subjects: 230
Study 36286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosorbents in subgroup Ib (n=57)
Number of subjects: 230
Study 36286887 — intervention group
Group type: COMPARATOR
Intervention: K-group (n=115) with respiratory symptoms
Number of subjects: 230
Study 32340903 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g/d native inulin
Number of subjects: 150
Study 32340903 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 150
Study 32340903 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 150
Study 34436555 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diet and lifestyle intervention utilizing short animated videos, delivered weekly for 5 weeks.
Number of subjects: 269
Study 35114186 — intervention group
Group type: COMPARATOR
Intervention: 125 cc/h normal saline
Number of subjects: 180
Study 35114186 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 cc/h normal saline
Number of subjects: 180
Study 33608403 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of insulin
Number of subjects: 206
Study 33608403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-39 (D-39) questionnaire
Number of subjects: 206
Study 33608403 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 206
Study 33608403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension comorbidity
Number of subjects: 206
Study 33608403 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c test
Number of subjects: 206
Study 36499011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb extract (RE) 12.5 mg per day
Number of subjects: 30
Study 36499011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb extract (RE) 25 mg per day
Number of subjects: 30
Study 36499011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 33963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab 3 mg/kg (ipi3)
Number of subjects: 1673
Study 33963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab 10 mg/kg (ipi10)
Number of subjects: 1673
Study 33963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 1-2 rash
Number of subjects: 1673
Study 36314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored home-based physiotherapy program (12 weeks)
Number of subjects: 21
Study 34332432 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 592
Study 34332432 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 592
Study 35249863 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticancer drugs
Number of subjects: 202
Study 32510759 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cognitive training intervention
Number of subjects: 0
Study 32510759 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-derived ANS segment at baseline
Number of subjects: 0
Study 33414106 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study 33414106 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI (controlling for diabetes)
Number of subjects: 0
Study 33414106 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 0
Study 32805594 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual milk administration by parents (MAP)
Number of subjects: 15
Study 32805594 — intervention group
Group type: COMPARATOR
Intervention: Electric syringe administration (ESA)
Number of subjects: 15
Study 36171608 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastinated specimens
Number of subjects: 96
Study 36171608 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional printed (3DP) models
Number of subjects: 96
Study 33400237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) group, n = 11; dose 40 × 10^6 Treg cells/kg of body weight
Number of subjects: 14
Study 33400237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) group, n = 3; dose 1.0 × 10^6 Treg cells
Number of subjects: 14
Study 33400237 — intervention group
Group type: COMPARATOR
Intervention: IV group
Number of subjects: 14
Study 33400237 — intervention group
Group type: EXPERIMENTAL
Intervention: IT group
Number of subjects: 14
Study 33400237 — intervention group
Group type: COMPARATOR
Intervention: IV and IT groups
Number of subjects: 14
Study 35114327 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting fruit (n=43)
Number of subjects: 123
Study 35114327 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=40)
Number of subjects: 123
Study 35114327 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting non-food products (n=40)
Number of subjects: 123
Study 33773809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 144
Study 33773809 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (AC)
Number of subjects: 144
Study 32404132 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using Tymo system or Walker View in addition to traditional therapy
Number of subjects: 195
Study 32404132 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 195
Study 35017258 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic (ANA) treatment (metamizole/dipyrone) with observational learning (positive video)
Number of subjects: 150
Study 35017258 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment with observational learning (positive video)
Number of subjects: 150
Study 35017258 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic (ANA) treatment (metamizole/dipyrone) with neutral video
Number of subjects: 150
Study 35017258 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment with neutral video
Number of subjects: 150
Study 35017258 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication or observational learning)
Number of subjects: 150
Study 34245136 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial thickness flap
Number of subjects: 10
Study 34245136 — intervention group
Group type: COMPARATOR
Intervention: Full thickness flap
Number of subjects: 10
Study 32005277 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV) therapy added to PCI and optimal medical management
Number of subjects: 0
Study 32005277 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy and PCI alone (control)
Number of subjects: 0
Study 32005277 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV) therapy
Number of subjects: 0
Study 36369456 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY liquid
Number of subjects: 2669
Study 36369456 — intervention group
Group type: COMPARATOR
Intervention: MenACWY licensed
Number of subjects: 2669
Study 33618779 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional strength training for 12 weeks
Number of subjects: 18
Study 33618779 — intervention group
Group type: COMPARATOR
Intervention: Control protocol without additional strength training
Number of subjects: 18
Study 34034826 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation compensation mechanism
Number of subjects: 100
Study 32130122 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool with electronic survey and tailored resources for physical activity (PA) prescription
Number of subjects: 530
Study 32130122 — intervention group
Group type: COMPARATOR
Intervention: Usual care from PCP (control group)
Number of subjects: 530
Study 35317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based physical activity program
Number of subjects: 0
Study 35317830 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34962979 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60/30mg
Number of subjects: 841
Study 34962979 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30/15mg
Number of subjects: 841
Study 32348101 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmin 600 mg once daily for 12 months
Number of subjects: 90
Study 32348101 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with rivaroxaban for six months and ECS for 12 months
Number of subjects: 90
Study 36501092 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC+CCA (620 mg GTC, 373 mg CCA, and 119 mg caffeine/day) for three weeks
Number of subjects: 11
Study 36501092 — intervention group
Group type: COMPARATOR
Intervention: PLA (0 mg GTC, 0 mg CCA, and 119 mg caffeine/day) for three weeks
Number of subjects: 11
Study 34569438 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU + SOS
Number of subjects: 250
Study 34569438 — intervention group
Group type: COMPARATOR
Intervention: CAU
Number of subjects: 250
Study 35688590 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted surgery (RAS)
Number of subjects: 300
Study 35688590 — intervention group
Group type: COMPARATOR
Intervention: Kinematic alignment (KA)
Number of subjects: 300
Study 33839919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG)
Number of subjects: 180
Study 33839919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG)
Number of subjects: 180
Study 33839919 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (SCG)
Number of subjects: 180
Study 32916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invasive strategy (cardiac catheterization and revascularization)
Number of subjects: 0
Study 32916291 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative strategy (medical therapy)
Number of subjects: 0
Study 32916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 0
Study 32916291 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 0
Study 32916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 0
Study 34856913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil lotion
Number of subjects: 121
Study 34856913 — intervention group
Group type: COMPARATOR
Intervention: Permethrin shampoo
Number of subjects: 121
Study 33253864 — intervention group
Group type: COMPARATOR
Intervention: Placebo and miltefosine (P + M)
Number of subjects: 150
Study 33253864 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GM-CSF and miltefosine (G + M)
Number of subjects: 150
Study 33253864 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral meglumine antimoniate (MA)
Number of subjects: 150
Study 34239299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based behavioral intervention (IG)
Number of subjects: 327
Study 34239299 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 327
Study 34239299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 327
Study 34956841 — intervention group
Group type: EXPERIMENTAL
Intervention: ROCO intervention plus care as usual
Number of subjects: 107
Study 34956841 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group receiving care as usual
Number of subjects: 107
Study 33161684 — intervention group
Group type: EXPERIMENTAL
Intervention: First mobilization trial
Number of subjects: 87
Study 33161684 — intervention group
Group type: EXPERIMENTAL
Intervention: Second mobilization trial with plerixafor
Number of subjects: 87
Study 32616150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex Activation Therapy (BAT) plus optimal medical management
Number of subjects: 245
Study 32616150 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimal medical management alone)
Number of subjects: 245
Study 35869690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg/m2/day (n = 32)
Number of subjects: 66
Study 35869690 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CYC) 5 mg/kg/day (n = 34)
Number of subjects: 66
Study 35869690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 66
Study 35869690 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CYC)
Number of subjects: 66
Study 32843517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic safety-netting toolkit embedded in EMIS-Web
Number of subjects: 60
Study 33740389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg GSH per day
Number of subjects: 20
Study 33740389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33230526 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 s.c. 120 mg biweekly until W28
Number of subjects: 343
Study 33230526 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 i.v. 3 mg/kg every 8 weeks until W22
Number of subjects: 343
Study 32297162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus over 30 minutes, followed by 1 mg/kg/h continuous infusion for 6 hours post-surgery)
Number of subjects: 41
Study 32297162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 41
Study 32297162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study 35089354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication regimens that stimulate type 2 and 4 angiotensin II receptors
Number of subjects: 8685
Study 35089354 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication regimens that inhibit type 2 and 4 angiotensin II receptors
Number of subjects: 8685
Study 35089354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating-only antihypertensive medications
Number of subjects: 8685
Study 35089354 — intervention group
Group type: COMPARATOR
Intervention: Inhibiting-only antihypertensive medications
Number of subjects: 8685
Study 32683067 — intervention group
Group type: EXPERIMENTAL
Intervention: MUS placed for documented SUI
Number of subjects: 134
Study 32683067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic MUS
Number of subjects: 134
Study 32683067 — intervention group
Group type: COMPARATOR
Intervention: No MUS placed
Number of subjects: 134
Study 35612382 — intervention group
Group type: COMPARATOR
Intervention: EVO (electrically evoked quadriceps contractions)
Number of subjects: 10
Study 35612382 — intervention group
Group type: COMPARATOR
Intervention: VOL (voluntary quadriceps contractions)
Number of subjects: 10
Study 35612382 — intervention group
Group type: COMPARATOR
Intervention: CON (no preexisting quadriceps fatigue)
Number of subjects: 10
Study 32498113 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation empagliflozin tablet under fasting condition
Number of subjects: 60
Study 32498113 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation Jardiance under fasting condition
Number of subjects: 60
Study 32498113 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation empagliflozin tablet under fed condition
Number of subjects: 60
Study 32498113 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation Jardiance under fed condition
Number of subjects: 60
Study 35131834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined gait training with music, metronome, and verbal cueing
Number of subjects: 132
Study 35131834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined gait training combined with actual gait training
Number of subjects: 132
Study 35131834 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual gait training
Number of subjects: 132
Study 35131834 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 matched healthy controls)
Number of subjects: 132
Study 34363293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum oxytocin administration
Number of subjects: 5484
Study 34363293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5484
Study 34363293 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation of infants whose mothers received intrapartum oxytocin
Number of subjects: 5484
Study 34363293 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation of infants whose mothers did not receive intrapartum oxytocin
Number of subjects: 5484
Study 32328912 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Number of subjects: 346
Study 32328912 — intervention group
Group type: COMPARATOR
Intervention: Attention control case management
Number of subjects: 346
Study 35450735 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 65
Study 35450735 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT ARTIC
Number of subjects: 65
Study 35450735 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 65
Study 33834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive sulfur coated urea with 130 kg N ha‐1
Number of subjects: 3
Study 33834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive sulfur coated urea with 94 kg N ha‐1
Number of subjects: 3
Study 33834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur coated urea with 94 kg N ha‐1
Number of subjects: 3
Study 33834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated fertilizers (neem-coated, sulfur-coated, bioactive sulfur-coated)
Number of subjects: 3
Study 33834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated fertilizers
Number of subjects: 3